

FIRST LIGHT 17 July 2020

### **RESEARCH**

L&T Infotech | Target: Rs 2,790 | +22% | BUY

Resilient show in a challenging quarter

# Diversified Financials | Q1FY21 Preview

Expect only gold finance NBFCs to shine

### **SUMMARY**

# L&T Infotech

L&T Infotech's (LTI) Q1FY21 revenue was in line with estimates, with a 4.7% QoQ CC decline due to a drop in the manufacturing and energy/utilities verticals. Operating margins bettered expectations backed by tight SG&A cost control. We keep FY21 EPS unchanged and increase FY22 EPS by ~3%, while raising our target P/E multiple by 20% to 24x given LTI's strong revenue mix, favourable offshore presence, client mining skills and robust leadership. Rolling valuations over, we have a new Jun'21 TP of Rs 2,790 (vs. Rs 2,230). BUY.

# Click here for the full report.

# Diversified Financials: Q1FY21 Preview

We expect MUTH and MGFL to register strong AUM growth of 19% and 30% YoY respectively in Q1FY21 as a secular credit crunch and run-up in gold prices act as tailwinds. With BAF, CIFC and MMFS focusing more on collections than disbursements, their AUM growth is likely to slow. HDFCAMC is expected to gain market share in liquid funds and maintain profitability. NAM could see some bounce back in equity and hybrid funds. Management comments on incremental provisions for Covid-19 will be a key monitorable.

## Click here for the full report.

## **TOP PICKS**

### **LARGE-CAPIDEAS**

Company	Rating	Target
Bajaj Finance	Buy	3,000
<u>Cipla</u>	Buy	690
GAIL	Buy	150
Petronet LNG	Buy	305
Tech Mahindra	Buy	690

### MID-CAP IDEAS

Company	Rating	Target
Alkem Labs	Buy	2,950
Chola Investment	Buy	200
<u>Laurus Labs</u>	Buy	630
Transport Corp	Buy	240
Mahanagar Gas	Sell	710

Source: BOBCAPS Research

## **DAILY MACRO INDICATORS**

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	0.63	1bps	(9bps)	(142bps)
India 10Y yield (%)	5.81	(1bps)	2bps	(53bps)
USD/INR	75.15	0.4	1.2	(9.2)
Brent Crude (US\$/bbl)	43.79	2.1	10.2	(31.2)
Dow	26,870	0.9	4.3	(1.3)
Shanghai	3,361	(1.6)	16.3	14.7
Sensex	36,052	0.1	8.5	(8.1)
India FII (US\$ mn)	14 Jun	MTD	CYTD	FYTD
FII-D	112.8	187.3	(14,094.7)	(4,335.2)
FII-E	(211.1)	(379.9)	(2,821.4)	3,781.6

Source: Bank of Baroda Economics Research

## **BOBCAPS** Research

research@bobcaps.in





**BUY**TP: Rs 2,790 | ▲ 22%

**L&T INFOTECH** 

IT Services

16 July 2020

# Resilient show in a challenging quarter

L&T Infotech's (LTI) Q1FY21 revenue was in line with estimates, with a 4.7% QoQ CC decline due to a drop in the manufacturing and energy/utilities verticals. Operating margins bettered expectations backed by tight SG&A cost control. We keep FY21 EPS unchanged and increase FY22 EPS by ~3%, while raising our target P/E multiple by 20% to 24x given LTI's strong revenue mix, favourable offshore presence, client mining skills and robust leadership. Rolling valuations over, we have a new Jun'21 TP of Rs 2,790 (vs. Rs 2,230). BUY.

Ruchi Burde | Seema Nayak research@bobcaps.in

Resilient operating performance: LTI's revenue declined 4.7% QoQ CC (-4.8% QoQ in USD terms), in line with our estimate (-4.8% QoQ CC). Utilisation excluding trainees dropped 100bps owing to the pandemic impact. Revenues were affected by significant weakness in the manufacturing and energy/utilities verticals which declined 16.4% and 10% QoQ respectively. Reported EBIT margins rose 70bps QoQ to 17.4%, outperforming our estimate of 17.2%, driven by tight control over SG&A (-120bps QoQ as % of sales).

Large deals slow but chase continues: Despite a challenging Q1, LTI bagged a large BFSI deal in the UK and added 16 new logos, including one Fortune-500 logo from the manufacturing vertical, to its client roster. While large deal wins slowed slightly in Q1 compared to the previous three quarters, management expects some sizeable contract signings in Q2FY21. As per LTI, the FY21 pipeline has risen 19% YoY and is steady across segments, barring the manufacturing and energy/utilities verticals.

**Comforting outlook:** Management expects Q1FY21 to be the trough and recovery to follow. LTI guided Q2 revenues to be flat with a positive bias, and management aims to keep EBIT margins rangebound around Q1 levels (of 17.4%).

## **KEY FINANCIALS**


Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	94,458	108,786	121,780	143,715	164,544
EBITDA (Rs mn)	18,835	20,291	23,412	27,922	32,180
Adj. net profit (Rs mn)	15,157	15,198	16,378	19,723	22,874
Adj. EPS (Rs)	86.5	86.4	93.3	112.4	130.3
Adj. EPS growth (%)	36.1	0.0	8.0	20.4	16.0
Adj. ROAE (%)	34.6	29.5	27.9	28.5	28.0
Adj. P/E (x)	26.5	26.5	24.5	20.4	17.6
EV/EBITDA (x)	21.2	19.7	17.2	14.4	12.3

Source: Company, BOBCAPS Research

Ticker/Price	LTI IN/Rs 2,291
Market cap	US\$ 5.4bn
Shares o/s	176mn
3M ADV	US\$ 3.8mn
52wk high/low	Rs 2,336/Rs 1,210
Promoter/FPI/DII	75%/8%/10%

Source: NSE

## STOCK PERFORMANCE



Source: NSE





# **DIVERSIFIED FINANCIALS**

Q1FY21 Preview

| 16 July 2020

# Expect only gold finance NBFCs to shine

We expect MUTH and MGFL to register strong AUM growth of 19% and 30% YoY respectively in Q1FY21 as a secular credit crunch and run-up in gold prices act as tailwinds. With BAF, C1FC and MMFS focusing more on collections than disbursements, their AUM growth is likely to slow. HDFCAMC is expected to gain market share in liquid funds and maintain profitability. NAM could see some bounce back in equity and hybrid funds. Management comments on incremental provisions for Covid-19 will be a key monitorable.

**Shubhranshu Mishra** research@bobcaps.in

**Key expectations:** We expect Bajaj Finance (BAF) to register a tepid quarter with declared AUM growth of 7% YoY and higher credit cost as management intends to make accelerated provisions for Covid-19. Gold finance NBFCs Muthoot Finance (MUTH)/Manappuram Finance (MGFL) are likely to post robust gold loan AUM growth of 19%/30% YoY as 30-50% of disbursals are digital and thus unaffected by the lockdown. We see benign credit costs for MUTH. As MGFL operates its vehicle finance business on the standalone book, credit cost is likely to inch up.

Among AMCs, our channel checks suggest HDFC AMC will gain market share in liquid funds, aiding profitability. We forecast a 24% YoY PAT increase for Nippon Life India AMC (NAM) assuming an uptick in equity and hybrid fund flows.

### **RECOMMENDATION SNAPSHOT**

Ticker	Rating
BAF IN	BUY
MUTH IN	BUY
MGFL IN	BUY
CIFC IN	BUY
MMFS IN	ADD
HDFCAMC IN	BUY
NAM IN	SELL

## FIG 1 - Q1FY21E EXPECTATIONS

TIGT - QII TZIE EXI ECIATIONS				
NBFCs	Q1FY21E (Rs bn)	Y <sub>0</sub> Y (%)	Q <sub>0</sub> Q (%)	Expectations
BAF				We expect stable spreads at ~11% levels and a 10% YoY rise in NII. AUM growth was
AUM	1,380.0	7.1	(6.2)	announced at 7% YoY. Credit cost is projected at ~420bps as the company has indicated
NII	40.6	10.0	(13.2)	accelerated provisioning for anticipated pandemic-related delinquencies. Expect a 33% YoY
PAT	8.1	(32.6)	(15.0)	decline in PAT.
MUTH				AUM is estimated to rise 19% YoY, maintaining its steady growth streak of the last eight
AUM	426.5	19.1	2.5	quarters. NII should increase 36% YoY backed by stable spreads. With the cost/income ratio
NII	16.5	35.6	1.1	at 27%, we expect operating profit to grow 46% YoY to Rs 12bn. Benign credit cost would aid
PAT	8.8	65.6	7.7	66% YoY PAT growth.
MGFL				
AUM	173.1	30.2	2.0	Gold loan growth is estimated at 30% YoY – a secular growth trend for the last eight quarters.
NII	7.8	23.3	1.0	We forecast stable spreads and 23% YoY NII growth. With high expenses but benign credit
PAT	3.5	60.5	4.0	cost, we project a 61% YoY increase in PAT to Rs 3.5bn.
CIFC				We expect tepid disbursements to mute AUM growth at 5% YoY as the company has been
AUM	602.5	4.8	(0.5)	focusing on collections rather than growth. We forecast NII growth of 10% led by stable
NII	10.4	9.9	2.0	spreads. Credit costs are likely to be higher due to accelerated provisioning for Covid-19,
PAT	2.5	(19.4)	NM	inducing a 20% YoY decline in PAT to Rs 2.5bn.
MMFS				
AUM	691.1	6.6	1.5	As ~75% of AUM is under moratorium, we expect a slow rundown of AUM, leading to 7% YoY
NII	13.6	5.7	(2.0)	growth. We forecast stable spreads, aiding 6% YoY growth in NII. Credit cost is likely to weigh
PAT	0.5	(33.4)	(79.4)	on profit; we thus project PAT of Rs 0.5bn.





## Disclaimer

### Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

ADD - Expected return from >+5% to +15%

**REDUCE** - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

#### Rating distribution

As of 30 June 2020, out of 95 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 49 have BUY ratings, 23 have ADD ratings, 12 are rated REDUCE, 10 are rated SELL and 1 is UNDER REVIEW. None of these companies have been investment banking clients in the last 12 months.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

#### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

EQUITY RESEARCH 17 July 2020

### **FIRST LIGHT**



We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

EQUITY RESEARCH 17 July 2020